Topics to be discussed through the clinical cases presented:

• Recent advances in the understanding of endocrine therapy resistance pathways in Breast Cancer, including PI3K/AKT/m-TOR and ESR1.
• Detailed review of intrinsic subtypes in triple negative tumors, emphasizing the challenges and opportunities in identifying new biomarkers.
• Relevance of the Her2-low biomarker
• Innovations in molecular biology and how these advances can be integrated into daily pathology practice to improve the diagnosis, prognosis and treatment of breast cancer.